What is Setmelanotide?
Setmelanotide is a melanocortin-4 receptor agonist studied in rare genetic forms of obesity. The featured trials enrolled people with POMC or LEPR deficiency, rather than general-population obesity.
Biological role or research focus
Rare genetic obesity.
This was not a full-year parallel placebo-controlled comparison. Small, genetically selected cohorts do not establish effectiveness in common obesity.
Names you may encounter
RM-493
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Melanocortin-4 receptor agonist peptide
- Research focus
- Rare genetic obesity
- Featured evidence
- Human open-label phase 3 studies with withdrawal periods
- Source check
- October 4, 2026
Quick answers
- Is Setmelanotide FDA approved?
- Yes. Imcivree (NDA 213793, approved November 2020) for obesity due to POMC, PCSK1 or LEPR deficiency, Bardet-Biedl syndrome, and acquired hypothalamic obesity (per current label). Source ↗
- Is Setmelanotide safe?
- Setmelanotide treats rare genetic or hypothalamic obesity; skin darkening, injection-site reactions and nausea are common, and the label warns of depression, sexual side effects and allergic reactions. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Setmelanotide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Setmelanotide in POMC or LEPR deficiency (2020) | Human open-label phase 3 studies with withdrawal periods | 10 participants with POMC deficiency and 11 with LEPR deficiency, aged six years or older. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human open-label phase 3 studies with withdrawal periods · 2020
Setmelanotide in POMC or LEPR deficiency
What did this publication test, and what did it find?
- Population / model
- 10 participants with POMC deficiency and 11 with LEPR deficiency, aged six years or older.
- Study design
- Open-label phase 3 studies with approximately one-year outcomes and blinded withdrawal periods for responders.
- Main finding
- At least 10% weight loss was reported in 8 of 10 POMC participants and 5 of 11 LEPR participants.
- Limits & context
- This was not a full-year parallel placebo-controlled comparison. Small, genetically selected cohorts do not establish effectiveness in common obesity.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
26 registered studies name Setmelanotide as an intervention; 5 are recruiting or under way, 0 have not started recruiting yet, 19 completed and 2 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 26 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Current Treatments for Patients with Genetic Obesity. ↗
Journal of clinical research in pediatric endocrinology · 2023 May 29 · Review, Journal Article
Read available full text ↗
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. ↗
The lancet. Diabetes & endocrinology · 2022 Dec · Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. ↗
Molecular metabolism · 2017 Oct · Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗
Pharmacotherapy for Obesity: Recent Updates. ↗
Clinical pharmacology : advances and applications · 2025 · Journal Article, Review
Read available full text ↗
Risks & interactions
Setmelanotide treats rare genetic or hypothalamic obesity; skin darkening, injection-site reactions and nausea are common, and the label warns of depression, sexual side effects and allergic reactions.
Safety is established by FDA labeling, based on trials in rare obesity conditions. The label lists no drug interactions and does not recommend use while breastfeeding; long-term data remain limited.
No condition tags: its FDA label does not single out these conditions. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
- Prior serious allergic reaction to setmelanotide or any ingredient
Serious risks
- Depression and suicidal thoughts
- Prolonged erections and other sexual side effects
- Serious allergic reactions, including anaphylaxis
- Skin darkening, darker existing moles and new moles
- Sudden adrenal insufficiency in acquired hypothalamic obesity
- High or low sodium in people with central diabetes insipidus
Common side effects
- skin darkening
- injection-site reactions
- nausea
- headache
- diarrhea
- abdominal pain
- vomiting
- spontaneous erections
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Imcivree (setmelanotide) prescribing information ↗
Safety & what remains unknown
Reported effects included injection-site reactions, pigmentation changes, and nausea. The small cohorts cannot exclude uncommon harms.
Evidence boundaries
This was not a full-year parallel placebo-controlled comparison. Small, genetically selected cohorts do not establish effectiveness in common obesity.
Official product context · checked October 4, 2026
The label includes warnings about depression or suicidal thoughts, sexual-arousal effects, and serious hypersensitivity. Current eligibility and precautions should be read in the complete product label rather than inferred from a receptor mechanism.
Source: DailyMed · Imcivree prescribing information · March 2026 indications ↗
Regulatory status
- U.S. FDA approval
- Approved
Imcivree (NDA 213793, approved November 2020) for obesity due to POMC, PCSK1 or LEPR deficiency, Bardet-Biedl syndrome, and acquired hypothalamic obesity (per current label). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Medicine status & clinical context
The March 2026 U.S. Imcivree label includes acquired hypothalamic obesity from age four and specified Bardet-Biedl, POMC, PCSK1, or LEPR-related obesity from age two, with condition-specific diagnostic requirements. General polygenic obesity is outside these labeled indications. The early rare-genetic-obesity trials on this page do not cover every population in the updated label.
The selected trials concern severe early-onset genetic obesity. Current eligibility and medicine precautions require product-specific clinical references.
Source: DailyMed · Imcivree prescribing information · March 2026 indications ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
Biology & proposed mechanism
MC4-receptor stimulation was tested in defined upstream genetic signaling disorders. A genetic-disease indication cannot be inferred for everyone with excess weight.
Questions worth asking
- Do these trials establish effectiveness for common obesity?
- What material, population, and route were actually studied?
- This was not a full-year parallel placebo-controlled comparison. Small, genetically selected cohorts do not establish effectiveness in common obesity.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Do these trials establish effectiveness for common obesity?
No. Their participants had defined rare genetic deficiencies; clinical eligibility depends on the exact condition and current product references.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
Source: DailyMed · Imcivree prescribing information · March 2026 indications ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
